4/23
11:52 am
mxct
MaxCyte, Inc. (NASDAQ: MXCT) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $11.00 price target on the stock.
Medium
Report
MaxCyte, Inc. (NASDAQ: MXCT) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $11.00 price target on the stock.
4/17
05:09 am
mxct
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth [Yahoo! Finance]
Medium
Report
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth [Yahoo! Finance]
4/10
08:05 am
mxct
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
Low
Report
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
4/8
09:23 am
mxct
Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer [Yahoo! Finance]
Low
Report
Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer [Yahoo! Finance]
4/2
08:40 am
mxct
MaxCyte signs strategic platform license with Be Biopharma [Seeking Alpha]
Medium
Report
MaxCyte signs strategic platform license with Be Biopharma [Seeking Alpha]
4/2
08:24 am
mxct
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) [Yahoo! Finance]
Medium
Report
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) [Yahoo! Finance]
4/2
08:05 am
mxct
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Medium
Report
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
3/18
03:16 pm
mxct
MaxCyte, Inc. (NASDAQ: MXCT) had its price target lowered by analysts at BTIG Research from $10.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
MaxCyte, Inc. (NASDAQ: MXCT) had its price target lowered by analysts at BTIG Research from $10.00 to $8.00. They now have a "buy" rating on the stock.
3/18
03:12 pm
mxct
MaxCyte, Inc. (NASDAQ: MXCT) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $11.00 price target on the stock.
Low
Report
MaxCyte, Inc. (NASDAQ: MXCT) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $11.00 price target on the stock.
3/17
04:47 am
mxct
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term [Yahoo! Finance]
Medium
Report
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term [Yahoo! Finance]
3/14
10:23 am
mxct
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]
Low
Report
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]
3/14
08:32 am
mxct
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/13
10:20 am
mxct
MaxCyte, Inc. (NASDAQ: MXCT) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
MaxCyte, Inc. (NASDAQ: MXCT) had its "outperform" rating re-affirmed by analysts at William Blair.
3/13
09:08 am
mxct
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years [Yahoo! Finance]
Low
Report
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years [Yahoo! Finance]
3/12
04:15 pm
mxct
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance [Yahoo! Finance]
Medium
Report
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance [Yahoo! Finance]
3/12
04:05 pm
mxct
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
Low
Report
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
3/5
11:35 am
mxct
MaxCyte, Inc. (NASDAQ: MXCT) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
MaxCyte, Inc. (NASDAQ: MXCT) had its "outperform" rating re-affirmed by analysts at William Blair.
3/4
04:22 pm
mxct
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results [Yahoo! Finance]
High
Report
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results [Yahoo! Finance]
3/4
04:05 pm
mxct
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
High
Report
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
2/9
08:05 am
mxct
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
Low
Report
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
2/9
02:08 am
mxct
Interim Management Statement [Yahoo! Finance]
Low
Report
Interim Management Statement [Yahoo! Finance]
2/9
02:08 am
mxct
Interim Management Statement Q1 2024 [Yahoo! Finance]
Low
Report
Interim Management Statement Q1 2024 [Yahoo! Finance]
1/30
08:10 am
mxct
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers [Yahoo! Finance]
Low
Report
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers [Yahoo! Finance]
1/30
08:05 am
mxct
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
Low
Report
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers